Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $3.80

ProQR Therapeutics (NASDAQ:PRQR) has been given a consensus rating of “Buy” by the four research firms that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $3.56.

Several analysts recently issued reports on PRQR shares. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of ProQR Therapeutics in a report on Thursday, March 14th. Chardan Capital raised their price target on ProQR Therapeutics from $2.00 to $2.50 and gave the stock a “buy” rating in a report on Thursday, March 14th. Finally, StockNews.com cut ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th.

Institutional Trading of ProQR Therapeutics

Several large investors have recently added to or reduced their stakes in PRQR. JPMorgan Chase & Co. increased its position in shares of ProQR Therapeutics by 37.8% during the 1st quarter. JPMorgan Chase & Co. now owns 977,794 shares of the biopharmaceutical company’s stock valued at $885,000 after purchasing an additional 268,315 shares during the period. BlackRock Inc. increased its position in shares of ProQR Therapeutics by 8.1% during the 1st quarter. BlackRock Inc. now owns 527,396 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 39,482 shares during the period. XTX Topco Ltd acquired a new position in shares of ProQR Therapeutics during the 1st quarter valued at $191,000. Renaissance Technologies LLC acquired a new position in shares of ProQR Therapeutics during the 1st quarter valued at $547,000. Finally, Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics during the 2nd quarter valued at $48,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Trading Down 3.8 %

PRQR stock opened at $2.29 on Friday. The company has a market cap of $186.31 million, a price-to-earnings ratio of -5.87 and a beta of 0.20. The company has a quick ratio of 3.54, a current ratio of 3.54 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $2.14 and a 200-day simple moving average of $1.81. ProQR Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.29.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. The business had revenue of $3.54 million during the quarter, compared to the consensus estimate of $27.88 million. On average, equities research analysts expect that ProQR Therapeutics will post -0.37 EPS for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).